Blueprint Medicines Corp

NASDAQ: BPMC
$94.15
-$2.47 (-2.6%)
Closing Price on November 22, 2024

BPMC Stock Chart and Intraday Price

BPMC Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 45 SIDNEY STREET, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 5,824.42M USD
Shares Outstanding 61,232,000
Blueprint Medicines Corp is a pioneer in developing targeted therapies for cancer and blood disorders. With a focus on precision medicine, they are advancing a pipeline of innovative treatments, including AYVAKIT for systemic mastocytosis and gastrointestinal tumors, and GAVRETO for certain types of lung and thyroid cancers. Their research also extends to tackling lung cancer with novel inhibitors and addressing rare conditions like fibrodysplasia ossificans progressive. Based in Cambridge, Massachusetts, Blueprint Medicines is committed to transforming patient outcomes through groundbreaking science.

BPMC Articles

Tuesday's Top Analyst Upgrades and Downgrades: Aflac, Comerica, Costco, Dollar General, Dominion Energy, Ford, Meta, T-Mobile, Walmart and More
Tuesday's top analyst upgrades and downgrades included Aflac, Cloudflare, Comerica, Comstock Resources, Costco Wholesale, Dollar General, Dominion Energy, Equitrans Midstream, Ford, Meta Platforms,...
Lee Jackson
Published:

Tuesday's Top Analyst Upgrades and Downgrades: Boeing, ChargePoint, Deere, Foot Locker, Salesforce, UPS, Vipshop, Walmart and More 
Tuesday’s top analyst upgrades and downgrades included Boeing, Boston Scientific, ChargePoint, Deere, Foot Locker, Horizon Therapeutics, Nu, Ross Stores, Salesforce, United Parcel Service, VF,...
Lee Jackson
Published:

Wells Fargo Cuts Targets and Coverage on Carnival and More
Wells Fargo issues a few calls and warns investors that these stocks could underperform the markets, even considering the bear market we are in now.
Chris Lange
Published:

Monday's Top Analyst Upgrades and Downgrades: Electronic Arts, Enterprise Products Partners, GoodRx, Netflix, Spirit Airlines, Take-Two Interactive, Target, Tesla and More
Monday's top analyst upgrades and downgrades included Docusign, Electronic Arts, Enterprise Products Partners, GoodRx, Netflix, Spirit Airlines, Take-Two Interactive Software, Target, Tesla and...
Lee Jackson
Published:

New Month, Renewed Optimism? Analysts Upgrade or Downgrade eBay, Infosys, Valero Energy and More
Wednesday’s additional top analyst upgrades and downgrades were on Danaher, eBay, GoodRx, Infosys, Valero Energy, Xylem and more.
Chris Lange
Published:

Thursday Afternoon's Top Analyst Upgrades and Downgrades: Autodesk, Check Point Software, DoorDash, Hilton, Nvidia, Upstart and More
Thursday afternoon's top analyst upgrades and downgrades included Autodesk, Check Point Software, DoorDash, Hilton, Nvidia, Upstart and more.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Apple, Applied Materials, BP, Bumble, Carrier, Harley-Davidson, Hess, Illumina, Johnson Controls and More
Wednesday's top analyst upgrades and downgrades included Apple, Applied Materials, BP, Bumble, Carrier, Harley-Davidson, Hess, Illumina, Johnson Controls and Lennar.
Lee Jackson
Published:

Top Analyst Upgrades and Downgrades: AbbVie, Alibaba, ADM, Best Buy, Intel, Lemonade, Nikola, Peloton, SAP, Under Armour, Wynn and More
Monday's top analyst upgrades and downgrades included AbbVie, Alibaba, Archer Daniels Midland, Best Buy, Intel, Nikola, Peloton Interactive, SAP, Under Armour and Wynn Resorts.
Jon C. Ogg
Published:
Last Updated:

What Does $1.7 Billion Mean to Blueprint Medicines?
Blueprint Medicines announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: AMD, Alcoa, Biomarin, Coca-Cola, Ford, GM, Intel, Kinder Morgan, Micron, Nvidia, Tesla, Twitter, Zillow and More
Tuesday's top analyst calls included Advanced Micro Devices, Alcoa, Biomarin Pharmaceutical, Coca-Cola, Ford, General Motors, Intel, Kinder Morgan, Micron Technology, Nvidia, Tesla, Twitter and...
Jon C. Ogg
Published: